Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Bought by Verition Fund Management LLC

Verition Fund Management LLC boosted its position in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 542.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 78,690 shares of the company’s stock after purchasing an additional 66,448 shares during the quarter. Verition Fund Management LLC owned about 0.06% of Organogenesis worth $225,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ORGO. Acadian Asset Management LLC raised its position in shares of Organogenesis by 2.4% in the second quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after buying an additional 72,696 shares during the last quarter. AQR Capital Management LLC grew its stake in Organogenesis by 76.9% in the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock worth $6,353,000 after acquiring an additional 986,132 shares during the period. Dimensional Fund Advisors LP raised its holdings in Organogenesis by 19.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock valued at $5,702,000 after acquiring an additional 333,123 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Organogenesis by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company’s stock worth $2,713,000 after purchasing an additional 23,675 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Organogenesis by 5.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 471,240 shares of the company’s stock worth $1,348,000 after purchasing an additional 24,878 shares during the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Organogenesis news, CEO Gary S. Gillheeney sold 18,416 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $3.65, for a total transaction of $67,218.40. Following the completion of the sale, the chief executive officer now directly owns 3,400,778 shares in the company, valued at $12,412,839.70. This represents a 0.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders sold 216,916 shares of company stock valued at $784,832. Insiders own 36.90% of the company’s stock.

Organogenesis Price Performance

Shares of NASDAQ:ORGO opened at $3.40 on Monday. The company has a market cap of $450.77 million, a P/E ratio of -56.67 and a beta of 1.73. The business has a fifty day simple moving average of $3.43 and a 200-day simple moving average of $2.99. Organogenesis Holdings Inc. has a 52 week low of $2.16 and a 52 week high of $4.70. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.11. The company had revenue of $115.18 million during the quarter, compared to analysts’ expectations of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter in the previous year, the business earned $0.02 EPS. Equities research analysts forecast that Organogenesis Holdings Inc. will post -0.07 EPS for the current year.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.